8月21日，*ST苏吴盘中上涨5.49%，截至09:47，报0.96元/股，成交1587.44万元，换手率2.39%，总市值 6.82亿元。 资料显示，江苏吴中医药发展股份有限公司位于苏州市吴中区东方大道988号，公司主要业务涉及医 药、医美和投资等行业，其中医药产业主要产品涵盖抗病毒/抗感染、免疫调节、抗肿瘤、消化系统、 心血管类等领域，医美产业则拥有韩国医美企业的产品在中国区的独家代理权益。公司在2020-2024五 年战略发展规划中，以医药大健康产业为核心发展方向，同时把医疗美容等作为新兴大健康子行业重点 培育，形成公司具有较强的市场竞争力和一定行业地位的大健康产业集群。 截至9月30日，*ST苏吴股东户数6.16万，人均流通股1.15万股。 2024年1月-9月，*ST苏吴实现营业收入16.47亿元，同比增长9.58%；归属净利润4508.06万元，同比增 长311.54%。 ...

Group 1 - The stock price of Fuyuan Pharmaceutical closed at 31.67 yuan on August 15, 2025, down 0.66% from the previous trading day [1] - The stock experienced significant volatility, with a high of 32.60 yuan and a low of 30.48 yuan, resulting in an amplitude of 6.65% [1] - The total trading volume for the day was 200,306 hands, with a transaction amount of 628 million yuan [1] Group 2 - Fuyuan Pharmaceutical is primarily engaged in chemical pharmaceuticals and medical devices, covering multiple therapeutic areas including cardiovascular, digestive, and anti-infection [1] - The company is headquartered in Beijing and is one of the stocks included in the Shanghai-Hong Kong Stock Connect [1] - A half-year performance briefing is scheduled for August 22, 2025, where the chairman and general manager will interact with investors online [1] Group 3 - On August 15, 2025, the net outflow of main funds was 36.41 million yuan, accounting for 0.24% of the circulating market value [1] - Over the past five trading days, the cumulative net inflow of main funds was 61.33 million yuan, representing 0.4% of the circulating market value [1]

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Wuzhong*) is facing potential forced delisting due to continuous financial fraud over four years, with the China Securities Regulatory Commission (CSRC) proposing a fine of 10 million yuan and indicating a "zero tolerance" stance towards such violations [1][5]. Group 1: Financial Misconduct - *ST Wuzhong* has been found to have falsified financial reports from 2020 to 2023, inflating revenue by 4.95 billion yuan, 4.69 billion yuan, 4.31 billion yuan, and 3.77 billion yuan, which accounted for 26.46%, 26.39%, 21.26%, and 16.82% of the reported revenue for those years respectively [2]. - The company also inflated total profits by 14.58 million yuan, 20.27 million yuan, 19.92 million yuan, and 21.22 million yuan, representing 2.89%, 51.65%, 26.42%, and 29.81% of the total profits for the respective years [2]. - Additionally, *ST Wuzhong* failed to disclose significant non-operating fund occupation by related parties, with amounts reaching 1.27 billion yuan, 1.39 billion yuan, 1.54 billion yuan, and 1.69 billion yuan from 2020 to 2023, which constituted 6.88%, 74.2%, 84.6%, and 96.09% of the net assets for those years [2]. Group 2: Regulatory Actions - The CSRC plans to impose a total fine of 30.5 million yuan on *ST Wuzhong* and its responsible individuals, with the actual controller, Qian Qunshan, facing a proposed 10-year ban from the securities market due to severe misconduct [3]. - Starting July 14, *ST Wuzhong*'s stock will be subject to delisting risk warnings due to its financial fraud, which has already led to previous warnings and a lack of opinion from the auditing firm on its 2024 financial report [4]. - The company has expressed its intention to cooperate with the CSRC and will exercise its rights to defend against the proposed penalties [4].

Core Viewpoint - *ST Suwu has been found guilty of multiple violations, including falsifying financial statements and failing to disclose the actual controlling shareholder, leading to a proposed fine of 10 million yuan and potential delisting from the stock exchange [1][6]. Summary by Sections Violations Identified - The company failed to disclose the actual controlling shareholder, with false records in annual reports from 2018 to 2023, incorrectly naming Qian Qunying as the actual controller instead of Qian Qunshan [2]. - *ST Suwu inflated revenue, costs, and profits through non-commercial trade activities with related companies, resulting in inflated revenues of 495 million yuan, 468 million yuan, 431 million yuan, and 377 million yuan for the years 2020 to 2023, which accounted for 26.46%, 26.39%, 21.26%, and 16.82% of reported revenues respectively [3]. - The company also failed to disclose significant non-operating fund occupations by related parties, with balances of 127 million yuan, 1.393 billion yuan, 1.543 billion yuan, and 1.693 billion yuan from 2020 to 2023, representing 6.88%, 74.2%, 84.6%, and 96.09% of net assets respectively [5]. Proposed Penalties - The China Securities Regulatory Commission (CSRC) proposed a fine of 10 million yuan for *ST Suwu and a 10-year market ban for Qian Qunshan, the actual controller and chairman [6][7]. - Additional fines were proposed for other board members, including 15 million yuan for Qian Qunshan, 2 million yuan for Qian Qunying, and 1.5 million yuan for Chen Yi [7]. Company Status - As of July 11, *ST Suwu's stock price was 2.42 yuan per share, with a total market capitalization of 1.723 billion yuan [10]. - The company has stated it will cooperate with the CSRC and exercise its rights to defend against the proposed penalties [9].

Core Viewpoint - *ST Suwu has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), indicating that the company may face major illegal delisting due to inflated revenue, costs, and profits in its annual reports from 2020 to 2023 [2][5][7]. Summary by Relevant Sections Administrative Penalty Notice - The notice states that *ST Suwu's subsidiaries engaged in non-commercial trade activities with related companies, leading to inflated financial figures [5][7]. - The company is at risk of being delisted under the Shanghai Stock Exchange's rules due to these violations [2][10]. Financial Impact - The inflated revenue figures from 2020 to 2023 were reported as follows: - 2020: 495 million yuan (26.46%) - 2021: 469 million yuan (26.39%) - 2022: 431 million yuan (21.26%) - 2023: 377 million yuan (16.82%) [7]. - The inflated costs were: - 2020: 481 million yuan (37.08%) - 2021: 448 million yuan (35.47%) - 2022: 411 million yuan (28.40%) - 2023: 355 million yuan (20.95%) [7]. - The inflated profit figures were: - 2020: 14.58 million yuan (2.89%) - 2021: 20.27 million yuan (51.65%) - 2022: 19.92 million yuan (26.42%) - 2023: 21.22 million yuan (29.81%) [7]. Company Response and Future Actions - *ST Suwu has issued its first risk warning regarding the potential for major illegal delisting [8]. - If the company receives a formal penalty decision confirming the violations, it will apply for a trading suspension and disclose relevant information [10]. - The Shanghai Stock Exchange will issue a notice regarding the potential termination of *ST Suwu's stock listing within five trading days of the suspension [10]. Recent Financial Performance - For the year 2024, *ST Suwu reported: - Revenue of 1.599 billion yuan, a decrease of 28.64% year-on-year - Net profit attributable to shareholders of 70.48 million yuan, compared to a loss of 71.95 million yuan in 2023 [10][11].

Core Viewpoint - *ST Suwu has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC), indicating that the company has inflated its operating income, operating costs, and profits from 2020 to 2023, which may lead to a forced delisting due to significant violations [2][10]. Summary by Sections Administrative Penalty Notice - On July 13, *ST Suwu announced it received an administrative penalty notice from the CSRC, which identified false records in its annual reports from 2020 to 2023 [2][10]. - The notice states that *ST Suwu's subsidiaries engaged in non-commercial trade activities with related companies, resulting in inflated financial figures [7]. Financial Impact - The inflated operating income for the years 2020 to 2023 was reported as follows: 4.95 billion, 4.69 billion, 4.31 billion, and 3.77 billion, representing 26.46%, 26.39%, 21.26%, and 16.82% of the reported operating income for those years, respectively [9]. - The inflated operating costs for the same years were 4.81 billion, 4.48 billion, 4.11 billion, and 3.55 billion, accounting for 37.08%, 35.47%, 28.40%, and 20.95% of the reported operating costs [9]. - The inflated total profits were 14.58 million, 20.27 million, 19.92 million, and 21.22 million, which constituted 2.89%, 51.65%, 26.42%, and 29.81% of the reported total profits for those years [10]. Regulatory Actions - The CSRC plans to impose a fine of 10 million yuan on *ST Suwu and a total of 20.5 million yuan in fines on its executives [10]. - The company has issued its first risk warning announcement regarding the potential for forced delisting due to significant violations [11][12]. Future Implications - If *ST Suwu receives a formal administrative penalty decision indicating significant violations, it will apply for a trading suspension and disclose relevant information promptly [14]. - The Shanghai Stock Exchange will issue a notice regarding the potential termination of *ST Suwu's listing within five trading days of the suspension [14]. Recent Financial Performance - In 2024, *ST Suwu reported an operating income of 1.599 billion, a year-on-year decrease of 28.64%, with a net profit attributable to shareholders of 70.48 million, compared to a net loss of 71.95 million in 2023 [15].

Core Viewpoint - The article discusses the ongoing regulatory issues faced by *ST Suwu, including the investigation of its chairman by the China Securities Regulatory Commission (CSRC) and the implications for the company's financial health and operations [2][3]. Group 1: Regulatory Issues - The chairman of *ST Suwu, Qian Qunshan, is under investigation by the CSRC, which has issued a notice of investigation. This investigation is focused solely on the chairman and is not expected to significantly impact the company's daily operations [3]. - In February 2024, *ST Suwu received a notice from the CSRC regarding suspected violations of information disclosure laws, which could lead to severe penalties, including potential delisting [3][8]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, a decrease of 28.64% year-on-year, and a net profit attributable to shareholders of 70.48 million yuan [6]. - The company has been issued a non-standard audit opinion due to issues related to the misuse of funds by related parties, with 769 million yuan reported as misappropriated and not returned [6]. Group 3: Business Operations - *ST Suwu operates in the pharmaceutical sector through its subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [4]. - The company aims to develop a dual-driven strategy focusing on both pharmaceutical and medical beauty sectors, leveraging opportunities in the health industry to enhance market competitiveness [6]. Group 4: Legal and Financial Risks - The company faces additional legal challenges, including a lawsuit against its subsidiary's former legal representative for alleged fraud related to export tax rebates, with the first court hearing scheduled for April 2025 [7]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [7].

Core Viewpoint - The chairman of *ST Suwu is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact the company's financial reporting and operations in the future [1][2]. Group 1: Investigation and Regulatory Actions - The CSRC has issued a notice of investigation against chairman Qian Qunshan, which is solely directed at him and is not expected to significantly affect the company's daily operations [1]. - The company has received a non-standard opinion on its 2024 annual report due to issues related to the occupation of funds, with a significant amount of 769 million yuan occupied by related parties [4]. - The company will provide weekly updates on the investigation's progress during the ongoing inquiry [2]. Group 2: Financial Performance - For the year 2024, *ST Suwu reported a revenue of 1.599 billion yuan, representing a year-on-year decrease of 28.64%, and a net profit attributable to shareholders of 70.48 million yuan [4]. - The company has received an audit report from Zhongxing Caiguanghua Accounting Firm that expresses an inability to provide an opinion on the financial statements due to the aforementioned issues [4]. Group 3: Business Operations and Strategy - *ST Suwu operates in the pharmaceutical sector through its wholly-owned subsidiary, Jiangsu Wuzhong Pharmaceutical Group, focusing on drug research, production, and sales, with key products in various therapeutic areas [2]. - The company aims to develop a dual-driven strategy focusing on both industrial development and capital operations, with plans to enhance its pharmaceutical core while nurturing the medical beauty biotechnology sector as a complementary industry [4]. Group 4: Legal and Financial Challenges - The company’s subsidiary, Jiangsu Wuzhong Import and Export Co., faced legal issues related to export tax fraud, with a court hearing scheduled for April 22, 2025 [5]. - Due to overdue loans, some of the company's bank accounts have been frozen, which may further impact its financing capabilities and business operations [5].